Context Therapeutics regains Nasdaq minimum bid price compliance

Context Therapeutics Inc.

Non-compliance with Minimum Bid Price Rule first disclosed on Jan 24, 2023; initial cure period ran to July 24, 2023.
On June 15, 2023, Nasdaq confirmed the company's common stock had a closing bid price of $1.00+ for 10 consecutive business days.
Nasdaq considers the matter closed; the company has regained compliance with Listing Rule 5550(a)(2).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.